Mira Pharmaceuticals Reports Material Agreement, Officer Changes
Ticker: MIRA · Form: 8-K · Filed: May 21, 2025 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | May 21, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, officer-changes, equity-sale
TL;DR
Mira Pharma inked a deal, saw exec changes, and sold some stock.
AI Summary
On May 15, 2025, Mira Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in its board and officer composition, including director departures and appointments. Additionally, details regarding compensatory arrangements for certain officers were disclosed.
Why It Matters
This filing indicates significant corporate actions, including new agreements and potential changes in leadership or compensation structures, which could impact the company's future operations and stock performance.
Risk Assessment
Risk Level: medium — The filing details material agreements, unregistered equity sales, and changes in directors/officers, suggesting potential shifts in strategy or financial structure that warrant closer examination.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- May 15, 2025 (date) — Date of earliest event reported
- Florida (location) — State of Incorporation
- 001-41765 (other) — Commission File Number
- 85-3354547 (other) — IRS Employer Identification No.
FAQ
What is the nature of the material definitive agreement entered into by Mira Pharmaceuticals, Inc. on May 15, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What were the reasons for the departure of directors or certain officers?
The filing mentions the departure of directors or certain officers, but the specific reasons for these departures are not detailed in the provided text.
Were there any unregistered sales of equity securities by Mira Pharmaceuticals, Inc.?
Yes, the filing explicitly states 'Unregistered Sales of Equity Securities' as an item information, indicating such sales occurred.
What is Mira Pharmaceuticals, Inc.'s state of incorporation and commission file number?
Mira Pharmaceuticals, Inc. is incorporated in Florida and its commission file number is 001-41765.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported in this 8-K filing is May 15, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 21, 2025 regarding MIRA PHARMACEUTICALS, INC. (MIRA).